Nivolumab for the treatment of bladder cancer.

about

The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer.Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.

P2860

Q49220712-157904C7-FAC0-491B-9D21-1E0A8D845895 Q52615452-A27FDD05-107B-48D0-B668-068371243E2E

P2860

Nivolumab for the treatment of bladder cancer.

Item

http://www.wikidata.org/entity/Q39454030

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Nivolumab for the treatment of bladder cancer.

@en

Nivolumab for the treatment of bladder cancer.

@nl

type

Item

label

Nivolumab for the treatment of bladder cancer.

@en

Nivolumab for the treatment of bladder cancer.

@nl

prefLabel

Nivolumab for the treatment of bladder cancer.

@en

Nivolumab for the treatment of bladder cancer.

@nl

P1476

Nivolumab for the treatment of bladder cancer.

@en

P2093

Oliver W Hakenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

P304

1309-1315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14712598.2017.1353076

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28737430

http://www.w3.org/2001/XMLSchema#string

Nivolumab for the treatment of bladder cancer.

about

P2860

P2860

Nivolumab for the treatment of bladder cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698